

JFW

Please Direct All Correspondence to Customer Number 20995

AMENDMENT / RESPONSE TRANSMITTAL

Applicant : Zhang, et al.
App. No : 10/826,478
Filed : April 16, 2004
For : DRUG SCREENING METHOD FOR
THE TREATMENT OF BRAIN
DAMAGE
Examiner : Petersen, C.
Art Unit : 1655

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 12, 2006

(Date)



Daniel Hart, Reg. No. 40,637

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) Response to Restriction/Election Requirement in 2 pages.
- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.



Daniel Hart
Registration No. 40,637
Attorney of Record
Customer No. 20,995
(619) 235-8550



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Zhang, et al.
Appl. No. : 10/826,478
Filed : April 16, 2004
For : DRUG SCREENING METHOD
FOR THE TREATMENT OF
BRAIN DAMAGE
Examiner : Petersen, C.
Group Art Unit : 1655

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 12, 2006

(Date)

Daniel Hart

Daniel Hart, Reg. No. 40,637

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT**Mail Stop Amendment**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In the Restriction Requirement mailed June 26, 2006, in the above-identified application, the Examiner identified the following patentably distinct inventions:

Group I: Claims 1-9 and 12-22, drawn to a method of screening for compounds, classified in class 435, subclass 4, for example.

Group II: Claim 10, drawn to a method of treating brain damage in humans resulting from hypoxia or ischemia, classified in class 514, subclass 1, for example.

Group III: Claim 11, drawn to pharmaceutical composition that comprises a substantially pure form of a falconoid, classified in class 514, subclass 1, for example.

In response to the Restriction Requirement, Applicants hereby elect Group I (claims 1-9 and 12-22), drawn to a method of screening for compounds. Claims 10 and 11 are hereby

Appl. No. : **10/826,478**
Filed : **April 16, 2004**

withdrawn as being directed toward a non-elected invention. Applicants reserve the right to pursue the non-elected claims in one or more divisional applications.


If there are any questions, the Examiner is invited to contact the undersigned at the telephone number listed below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 12, 2006

By: _____



Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 20,995

(619) 235-8550

2738563
071006